# DFTX (Definium Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Definium Therapeutics, Inc. reported $1.07B in total assets and a net loss of $337.5M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/DFTX
- Markdown: https://convexityos.com/fundamentals/DFTX.md
- SEC CIK: 0001813814
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:16 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001813814&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$254.2M | Operating profit |
| Net Income | FY 2025 | -$337.5M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$2.46 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $1.05B | Total debt: $36.66M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $117.7M | $65.30M | $52.12M | $36.17M | $34.79M | $18.63M |
| Total Operating Expenses | $166.3M | $103.9M | $93.87M | $66.33M | $93.85M | $33.03M |
| **Operating Income** | -$166.3M | -$103.9M | -$93.87M | -$66.33M | -$93.85M | -$33.03M |
| Interest Income | $10.96M | $11.56M | $5.58M | -- | -- | -- |
| Interest Expense | $5.48M | $2.28M | $920K | -- | -- | -- |
| Income Before Tax | -$183.8M | -$108.7M | -$95.73M | -$56.80M | -$94.19M | -$33.94M |
| Income Tax Expense | $0 | -- | -- | -- | -$1.16M | -- |
| **Net Income** | -$183.8M | -$108.7M | -$95.73M | -$56.80M | -$93.04M | -$33.94M |
| Basic EPS | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$51.00 | -$1.95 |
| **Diluted EPS** | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$51.00 | -$1.95 |
| Basic Shares Outstanding | 89.3M | 70.5M | 39.2M | 30.9M | 1.8M | 17.7M |
| Diluted Shares Outstanding | 89.3M | 70.5M | 39.2M | 30.9M | 1.8M | 17.7M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $46.14M | $48.66M | $41.48M | $33.52M | $30.98M | $29.81M | $23.36M | $21.76M |
| Total Operating Expenses | $72.28M | $75.08M | $59.22M | $47.58M | $45.67M | $40.90M | $32.16M | $32.46M |
| **Operating Income** | -$72.28M | -$75.08M | -$59.22M | -$47.58M | -$45.67M | -$40.90M | -$32.16M | -$32.46M |
| Interest Income | $10.14M | $3.59M | $3.46M | $3.49M | $2.26M | $2.77M | $2.43M | $3.28M |
| Interest Expense | $1.15M | $1.23M | $1.25M | $1.27M | $1.27M | $2.34M | $602K | $656K |
| **Net Income** | -$50.96M | -$159.0M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | -$23.35M | -$34.74M |
| Basic EPS | -$0.37 | -$1.44 | -$0.71 | -- | -$0.78 | -$0.50 | -$0.27 | -- |
| **Diluted EPS** | -$0.46 | -$1.44 | -$0.71 | -- | -$0.78 | -$0.50 | -$0.35 | -- |
| Basic Shares Outstanding | 135.9M | 110.7M | 108.8M | -- | 85.9M | 85.3M | 85.1M | -- |
| Diluted Shares Outstanding | 137.3M | 110.7M | 108.8M | -- | 85.9M | 85.3M | 87.1M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $257.8M | $273.7M | $99.70M | $142.1M | $133.5M | $80.09M |
| Short-Term Investments | $153.8M | $0 | -- | -- | -- | -- |
| **Cash & Short-Term Investments** | $411.6M | $273.7M | $99.70M | $142.1M | $133.5M | $80.09M |
| **Total Current Assets** | $419.3M | $281.6M | $103.9M | $146.1M | $137.2M | $81.52M |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $0 |
| Intangible Assets | -- | $0 | $527K | $3.69M | $6.87M | -- |
| Long-Term Investments | -- | $0 | -- | -- | -- | -- |
| Other Non-Current Assets | $862K | $613K | $224K | $331K | -- | -- |
| **Total Non-Current Assets** | $20.78M | $20.53M | $20.67M | $23.94M | $26.79M | $0 |
| **Total Assets** | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M | $81.52M |
| Accounts Payable | $5.35M | $2.01M | $4.14M | $2.11M | $4.18M | $2.02M |
| **Total Current Liabilities** | $66.70M | $38.85M | $32.25M | $17.89M | $10.41M | $3.01M |
| Long-Term Debt | $40.58M | $21.85M | $14.13M | -- | -- | -- |
| Other Non-Current Liabilities | $496K | -- | $32K | $1.18M | $1.93M | -- |
| **Total Non-Current Liabilities** | $41.08M | $21.85M | $14.16M | $1.18M | $1.93M | $2.64M |
| **Total Liabilities** | $107.8M | $60.70M | $46.41M | $19.08M | $12.34M | $5.65M |
| **Total Debt (incl. Leases)** | $40.58M | $21.85M | $14.13M | -- | -- | -- |
| Common Stock | -- | $0 | $0 | -- | -- | -- |
| Retained Earnings | -$582.7M | -$398.9M | -$290.2M | -$194.5M | -$137.7M | -$44.64M |
| Accumulated Other Comp. Income | $1.08M | $819K | $343K | $627K | $1.05M | $284K |
| **Total Stockholders' Equity** | $332.3M | $241.4M | $78.13M | $150.9M | $151.7M | $75.87M |
| Total Equity | $332.3M | $241.4M | $78.13M | $150.9M | $151.7M | $75.87M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $241.2M | $655.3M | $262.5M | $257.8M | $19.96M | $33.39M | $82.85M | $273.7M |
| Short-Term Investments | $805.7M | $428.6M | $110.9M | $153.8M | $189.1M | $149.6M | $129.6M | $0 |
| **Cash & Short-Term Investments** | $1.05B | $1.08B | $373.4M | $411.6M | $209.1M | $183.0M | $212.4M | $273.7M |
| **Total Current Assets** | $1.05B | $1.09B | $380.6M | $419.3M | $215.8M | $189.1M | $221.7M | $281.6M |
| Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| Intangible Assets | -- | -- | -- | -- | -- | -- | -- | $0 |
| Long-Term Investments | -- | -- | -- | -- | -- | $54.86M | $33.10M | $0 |
| Other Non-Current Assets | $2.61M | $880K | $812K | $862K | $1.15M | $1.17M | $606K | $613K |
| **Total Non-Current Assets** | $22.52M | $20.80M | $20.73M | $20.78M | $21.07M | $75.95M | $53.62M | $20.53M |
| **Total Assets** | $1.07B | $1.11B | $401.3M | $440.1M | $236.9M | $265.1M | $275.3M | $302.2M |
| Accounts Payable | $9.28M | $6.96M | $7.13M | $5.35M | $8.11M | $4.22M | $2.27M | $2.01M |
| **Total Current Liabilities** | $67.73M | $157.2M | $81.11M | $66.70M | $65.42M | $37.96M | $30.48M | $38.85M |
| Long-Term Debt | $36.66M | $36.47M | $40.77M | $40.58M | $40.38M | $41.19M | $22.04M | $21.85M |
| Other Non-Current Liabilities | $1.86M | $549K | $559K | $496K | $519K | $543K | -- | -- |
| **Total Non-Current Liabilities** | $38.52M | $37.02M | $41.33M | $41.08M | $40.90M | $41.73M | $22.04M | $21.85M |
| **Total Liabilities** | $106.2M | $194.2M | $122.4M | $107.8M | $106.3M | $79.69M | $52.52M | $60.70M |
| **Total Debt (incl. Leases)** | $36.66M | $36.47M | $40.77M | $40.58M | $40.38M | $41.79M | $22.04M | $21.85M |
| Common Stock | -- | -- | -- | -- | -- | -- | -- | $0 |
| Retained Earnings | -$869.7M | -$818.8M | -$659.8M | -$582.7M | -$532.2M | -$465.0M | -$422.2M | -$398.9M |
| Accumulated Other Comp. Income | -$829K | $417K | $824K | $1.08M | $1.00M | $807K | $802K | $819K |
| **Total Stockholders' Equity** | $968.0M | $918.7M | $278.8M | $332.3M | $130.6M | $185.4M | $222.8M | $241.4M |
| Total Equity | $968.0M | $918.7M | $278.8M | $332.3M | $130.6M | $185.4M | $222.8M | $241.4M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$183.8M | -$108.7M | -$95.73M | -$56.80M | -$93.04M | -$33.94M |
| Stock-Based Compensation | $20.10M | $16.91M | $15.18M | $13.71M | $42.72M | $7.41M |
| Change in Payables | $3.34M | -$2.13M | $2.02M | -$2.06M | $1.28M | $544K |
| **Operating Cash Flow** | -$131.6M | -$79.13M | -$64.36M | -$50.14M | -$45.82M | -$23.60M |
| Acquisitions, Net | -- | -- | -- | -- | -$297K | -- |
| Purchases of Investments | -$268.4M | $0 | -- | -- | -- | -- |
| **Investing Cash Flow** | -$151.6M | $0 | -- | -- | -$297K | -- |
| Common Stock Issued | $0 | $984K | $7.53M | $42.30M | $81.92M | $71.99M |
| **Financing Cash Flow** | $267.3M | $253.2M | $21.85M | $59.05M | $98.82M | $96.70M |
| **Net Change in Cash** | -$15.90M | $174.0M | -$42.44M | $8.60M | $53.45M | $73.39M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$50.96M | -$159.0M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | -$23.35M | -$34.74M |
| Stock-Based Compensation | $10.78M | $9.64M | $7.13M | $5.60M | $5.82M | $5.25M | $3.43M | $3.95M |
| Change in Payables | $2.31M | -$162K | $1.78M | -$2.77M | $3.90M | $1.95M | $258K | -$139K |
| **Operating Cash Flow** | -$52.98M | -$52.78M | -$42.63M | -$42.98M | -$29.57M | -$29.60M | -$29.42M | -$25.35M |
| Purchases of Investments | -$442.8M | -$355.7M | $0 | -$6.02M | -$26.59M | -$73.29M | -$162.5M | $0 |
| **Investing Cash Flow** | -$372.8M | -$316.7M | $42.00M | $34.98M | $15.41M | -$39.54M | -$162.5M | $0 |
| **Financing Cash Flow** | $11.66M | $762.3M | $5.31M | $245.9M | $749K | $19.65M | $1.00M | $3.81M |
| **Net Change in Cash** | -$414.1M | $392.7M | $4.68M | $237.9M | -$13.43M | -$49.46M | -$190.9M | -$21.54M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -55.3% | -45.0% | -122.5% | -37.6% | -61.3% | -44.7% |
| Return on Assets (ROA) | -41.8% | -36.0% | -76.9% | -33.4% | -56.7% | -41.6% |
| Current Ratio | 6.29x | 7.25x | 3.22x | 8.16x | 13.18x | 27.10x |
| Quick Ratio | 6.17x | 7.05x | 3.09x | 7.94x | 12.83x | 26.63x |
| Debt to Equity | 0.12x | 0.09x | 0.18x | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -34.9% | -38.5% | -85.2% | -55.3% | -128.7% | -61.8% | -34.8% | -45.0% |
| Return on Assets (ROA) | -31.4% | -31.8% | -59.2% | -41.8% | -71.0% | -43.2% | -28.2% | -36.0% |
| Current Ratio | 15.53x | 6.95x | 4.69x | 6.29x | 3.30x | 4.98x | 7.27x | 7.25x |
| Quick Ratio | 15.46x | 6.89x | 4.60x | 6.17x | 3.20x | 4.82x | 6.97x | 7.05x |
| Debt to Equity | 0.04x | 0.04x | 0.15x | 0.12x | 0.31x | 0.23x | 0.10x | 0.09x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
